ZIOPHARM Oncology (NASDAQ:ZIOP)‘s stock had its “hold” rating reaffirmed by Zacks Investment Research in a report issued on Saturday.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Other analysts also recently issued research reports about the stock. BidaskClub downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday. ValuEngine downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Thursday, December 14th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.67.

ZIOPHARM Oncology (ZIOP) traded up $0.10 during trading hours on Friday, hitting $4.36. 1,311,411 shares of the stock traded hands, compared to its average volume of 1,734,040. The company has a market cap of $604.76, a price-to-earnings ratio of -8.38 and a beta of 1.44. ZIOPHARM Oncology has a 12 month low of $3.77 and a 12 month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. The business’s revenue was up .0% compared to the same quarter last year. analysts forecast that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of ZIOPHARM Oncology stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average price of $4.68 per share, with a total value of $30,139.20. Following the transaction, the chief executive officer now owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZIOP. Vanguard Group Inc. grew its position in ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after purchasing an additional 553,933 shares during the period. State Street Corp boosted its holdings in ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after acquiring an additional 517,057 shares during the last quarter. Northern Trust Corp boosted its holdings in ZIOPHARM Oncology by 10.1% during the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after acquiring an additional 149,067 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in ZIOPHARM Oncology during the 3rd quarter worth $746,000. Finally, Tudor Investment Corp ET AL boosted its holdings in ZIOPHARM Oncology by 390.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 50,395 shares during the last quarter. 40.23% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/zacks-investment-research-reiterates-hold-rating-for-ziopharm-oncology-ziop/1806066.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with Analyst Ratings Network's FREE daily email newsletter.